Clinical Oncology

[SARS-CoV-2 infection-lung demage. Lung cancer and Covid-19 in the TERAVOLT clinical studys]

SZONDY Klára1, FUTÁCSI Balázs2, KIS Sándor1

FEBRUARY 28, 2021

Clinical Oncology - 2021;8(1)

[Hopefully, towards the end of the Covid-19 pandemic, we intend to provide a brief overview of the infection, the pathogen, most effective treatment options, lung damage, and the results of TERAVOLT clinical trial, about patients with lung cancer, treated or not-treated, infected by SARS-CoV-2 virus. Tried to summarize the new diagnostic and therapy rules (bronchoscopy, chest x-ray, chest CT), and the potential new vaccinations. Authors provide a brief overview of the treatment of respiratory and cancer patients during infection, the continuation of inhalation drugs, immunotherapy and/or chemotherapy.]

AFFILIATIONS

  1. Terézvárosi Egészségügyi Szolgálat, Tüdőgondozó, Budapest
  2. Semmelweis Egyetem, Radiológiai Klinika, Budapest

COMMENTS

0 comments

Further articles in this publication

Clinical Oncology

[Comprehensive care of the carcinoma of the uterine cervix]

ÁROKSZÁLLÁSI Anita

[Cancer of the uterine cervix is a major world health problem for women. Yearly around half a million new cases are diagnosed with cervical cancer having leaded nearly 300,000 deaths in 2018 globally. In developed countries epidemiological data is improving due to the vaccination policy against “high risk” human papilloma viruses (hrHPV) and the population-based screening programs by cytology or hrHPV-testing. However, in developing regions the incidence and mortality data are still dismal. Precancerous lesions and early-stage cervical cancer can be cured solely by surgical approach. Pathological risk factors will determine the need of postoperative radio- or chemoradiotherapy. In advanced-stage disease chemoradiotherapy or systemic therapy are the available options. As a considerable part of the patients are young female, there are some special issues to be faced with like the desire of fertility-sparing or cervical cancer diagnosed in pregnancy. Clinically occult cervical carcinoma recognized after simple hysterectomy is another complex therapeutic field. In modern oncology, the biological agents have also emerged in the therapeutic field of advanced cases: bevacizumab combined with cisplatin and paclitaxel as first line therapy; and pembrolizumab as second line option for tumors with microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) or for tumors express PD-L1 (Combined Positive Score [CPS] ≥1.) The present work provides a short summary of the current literature about the screening, staging, comprehensive management and follow-up of uterine cervical cancer.]

Clinical Oncology

[The benefits of vaccination in risk groups]

BÉRES Zsuzsanna Katalin

[As the average age increases, the prevention of infectious diseases is of paramount importance, not just during a pandemic. In terms of volume and complications, pneumococcal and influenza infections are among the top 10 most common causes of death. Timely and properly applied vaccination is an effective weapon against both diseases. This fact is confirmed by several clinical trials. The advent of conjugate vaccination has been a milestone in the history of vaccination. It is important that affected groups are protected from the two seasonal infectious diseases as soon as possible. Always use the conjugate vaccine first to develop protection against pneumococcus, the polysaccharide vaccination, which only broadens the spectrum, is proposed in the second step and needs to be considered for at-risk groups. Influenza vaccination should be repeated annually. The two vaccines can be given at the same time, there is no need to keep the interval.]

Clinical Oncology

[Treatment of cancer associated venous thromboembolism in the age of direct oral anticoagulants]

AY C, BEYER-WESTENDORF J, PABINGER I

[Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging due to complications-including bleeding and potential drug-drug interactions with chemotherapy-associated with vitamin K antagonists and inconvenience of low-molecular-weight heparin (LMWH). Direct oral anticoagulants (DOACs) could partially overcome these issues, but until recently there were no large clinical trials assessing their efficacy and safety in cancer patients. This review summarizes clinical treatment guidelines, prior clinical and real-world evidence for anticoagulant choice, recent clinical trials assessing DOACs for cancer-associated VTE (i.e. Hokusai-VTE Cancer, SELECT-D, CARAVAGGIO, and ADAM VTE), and special considerations for DOAC use. Based on established data, clinical guidelines recommend patients with cancer-associated VTE receive LMWH treatment of at least 3-6 months. Nevertheless, LMWH is underused and associated with poor compliance and persistence in these patients relative to oral anticoagulants. Clinical data supporting DOAC use in cancer patients are becoming available. In Hokusai-VTE Cancer, edoxaban was noninferior to dalteparin for the composite of recurrent VTE and major bleeding (12.8% versus 13.5%), with numerically lower recurrent VTE (7.9% versus 11.3%) and significantly higher major bleeding (6.9% versus 4.0%); only patients with gastrointestinal cancer had significantly higher risk of bleeding with edoxaban. In SELECT-D, rivaroxaban had numerically lower VTE recurrence (4% versus 11%), comparable major bleeding (6% versus 4%), and numerically higher clinically relevant nonmajor bleeding (13% versus 4%) versus dalteparin. Most bleeding events were gastrointestinal or urologic; patients with esophageal/gastroesophageal cancer had higher rates of major bleeding with rivaroxaban (36% versus 11%). For comparison of apixaban versus dalteparin, CARAVAGGIO is ongoing, and preliminary results from ADAM VTE are favorable. This review concludes that DOACs appear to be reasonable alternatives to LMWH for treatment of cancer-associated VTE. In patients with gastrointestinal cancer, DOAC use should be considered on a case-by-case basis with consideration of the relative risks and benefits. Kulcsszavak: venous thromboembolism, cancer, treatment, direct oral anticoagulants Nevertheless, LMWH is underused and associated with poor compliance and persistence in these patients relative to oral anticoagulants. Clinical data supporting DOAC use in cancer patients are becoming available. In Hokusai-VTE Cancer, edoxaban was noninferior to dalteparin for the composite of recurrent VTE and major bleeding (12.8% versus 13.5%), with numerically lower recurrent VTE (7.9% versus 11.3%) and significantly higher major bleeding (6.9% versus 4.0%); only patients with gastrointestinal cancer had significantly higher risk of bleeding with edoxaban. In SELECT-D, rivaroxaban had numerically lower VTE recurrence (4% versus 11%), comparable major bleeding (6% versus 4%), and numerically higher clinically relevant nonmajor bleeding (13% versus 4%) versus dalteparin. Most bleeding events were gastrointestinal or urologic; patients with esophageal/gastroesophageal cancer had higher rates of major bleeding with rivaroxaban (36% versus 11%). For comparison of apixaban versus dalteparin, CARAVAGGIO is ongoing, and preliminary results from ADAM VTE are favorable. This review concludes that DOACs appear to be reasonable alternatives to LMWH for treatment of cancer-associated VTE. In patients with gastrointestinal cancer, DOAC use should be considered on a case-by-case basis with consideration of the relative risks and benefits.]

Clinical Oncology

[(K)RAS mutant human cancers]

TÍMÁR József, RÁSÓ Erzsébet

[RAS mutation is the most frequent oncogenic alteration in human cancers and K-RAS is far the most frequently involved among the RAS family members followed by N-RAS. Beside the emblematic K-RAS mutant cancers, pancreatic-, colorectal- and lung adenocarcinomas, urogenital cancers are also belong to this family of malignancies. It is important that K-RAS mutation frequencies are relatively stable around the world in various cancer types with one exeption: lung adenocarcinoma. The variant allele frequencies of K-RAS seems to be cancer-type specific reflecting various carcinogenic processes. Beside point mutation K-RAS allelic imbalances are also frequent in human cancers leading to the predominance of the mutant allele. K-RAS mutant cancers are characterized by typical cancer-type specific co-occurring mutations and well-defined gene expression signatures. ]

Clinical Oncology

[Rehabilitation of cancer patients]

DANK Magdolna, PÉNTEK Irén, JUHÁSZ Ágnes, HAJDÚ Anett

[In our country, the number of neoplastic diseases is constantly increasing. Based on the KSH data 376,709 people had neoplastic diseases in 2017. The disease is a long-term, chronic process, and the physical burden caused by treatments makes it difficult to maintain the physical and mental balance of patients. The quality of life of the neoplastic diseases patient changes, his ability to work will be reduced, his role in the family will be changed, his physical and emotional strength. These problems can be remedied by rehabilitation interventions, but oncology rehabilitation in many places in Hungary is unfortunately not part of the standard of care. In fact, oncology rehabilitation differs from the rehabilitation plan for other diseases. The oncology rehabilitation plan should be treated more flexible and more differentiated, changes due to disease and treatment should always be considered. As a result, the demand for evidence-based rehabilitation interventions is growing therefore, our aim is to apply international literature overview of rehabilitation options for neoplastic diseases patients, including metastatic patients which can be used to reduce pain as a side effect of treatments, musculoskeletal and nutritional problems this will allow for a significant improvement in the quality of life of patients.]

All articles in the issue

Related contents

Lege Artis Medicinae

[Vaccines against COVID-19 pandemic]

FALUS András, SZEKANECZ Zoltán

[The rapidly spreading SARS-CoV2 respiratory virus has evoked an epidemic with serious aftermath around the world. In addition to the health effects, the global economic damage is actually unpredictable. At the same time, the pandemic has launched a series of unprecedented collaborative scientific research, including the development of vaccines. This study summarizes up-to-date information on vaccines, immune memory, and some emerging clinical effects.]

Journal of Nursing Theory and Practice

[Correlations Between Burnout and Socio-demographic and Workplace Related Factors Among Health-care Workers During The Covid-19 Pandemics]

NÉMETH Anikó, IRINYI Tamás

[The present study aimed to assess the level of burn-out among health-care workers in 2020 and its correlations with socio-demographic and workplace related factors. The cross-sectional study was conducted by the means of a self-constructed online survey in the beginning of 2021. The responses of 1965 people were analysed with the help of SPSS 23.0. Descriptive statistics, chi-square and Kruskal-Wallis probes were run (p<0.05). Severe burnout was present in 46.7% of the responders. Age, marital status, type of health-care provided and years spent in the health-care system didn’t show any correlation with burnout. Unsure vision, opinion about salary raise and uncertainty at the workplace influenced the level of burnout significantly (p<0.000). The mental health of health-care workers is in continuous decline, in which the COVID-19 pandemic might play a big role. People with worse mental health feel more uncertain regarding their future and job; this might make providing health-care more and more difficult.]

Clinical Neuroscience

Acute transverse myelitis after inactivated COVID-19 vaccine

ERDEM Şimşek Nazan, DEMIRCI Seden, ÖZEL Tuğba , MAMADOVA Khalida, KARAALI Kamil , ÇELIK Tuğba Havva , USLU Ilgen Ferda, ÖZKAYNAK Sibel Sehür

Vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been rapidly developed to prevent coronavirus disease 2019 (COVID-19) pandemic. There is increasing safety concerns regarding COVID-19 vaccines. We report a 78-year old woman who was presented with tetraparesis, paresthesias of bilateral upper extremities, and urinary retention of one-day duration. Three weeks before these symptoms, she was vaccinated with CoronaVAC vaccine (Sinovac Life Sciences, China). Spine magnetic resonance imaging showed longitudinally extensive transverse myelitis (TM) from the C1 to the T3 spinal cord segment. An extensive diagnostic workup was performed to exclude other possible causes of TM. We suggest that longitudinally extensive TM may be associated with COVID-19 vaccination in this case. To the best of our knowledge, this is the first report of longitudinally extensive TM developing after CoronaVac vaccination. Clinicians should be aware of neurological symptoms after vaccination of COVID-19.

Clinical Neuroscience

The effect of sniffing Turkish coffee on olfactory disorders in COVID-19 patients: An experimental clinical study

BULBULOGLU Semra, ALTUN Yasar

The current study aimed to examine the effect of sniffing Turkish coffee on the sense of smell in COVID-19 patients. This study utilized the experiment-control method. Data were collected using a patient and disease information form and the Connecticut Chemosensory Clinical Research Center (CCCRC) Test. An experimental group of patients sniffed Turkish coffee, and the coffee’s effect on the patients’ sense of smell was examined. All data were analyzed using SPSS version 25 (IBM). Of the patients in the experimental group, 25% had moderate hyposmia, 58.3% had severe hyposmia, and 16.7% had anosmia prior to sniffing Turkish coffee. After sniffing the Turkish coffee, 13.3% of these patients regained their ability to smell normally, while 18.3% had mild hyposmia, 45% had moderate hyposmia, 6.7% had severe hyposmia, and 16.7% had anosmia. There was no difference in the control group between first and second measurement. COVID-19 patients who sniffed Turkish coffee intermittently regained some of their sense of smell for one hour. Turkish coffee is cheap, fragrant, widely available, and easy to access. Therefore, results of this study suggest that it may be recommended for treating olfactory disorder in COVID-19 patients.

Clinical Neuroscience

The effect of starting a meal with salt and date palm on taste impairment caused by COVID-19

ALTUN Yasar , BULBULOGLU Semra

This study was conducted to examine the effect of starting a meal with salt and date palm on the sense of taste in COVID-19 patients. This study was conducted using a randomized controlled method. Patient and disease information forms and Visual Analog Scale were used for data collection. Salt and date palm were used to stimulate the sense of taste in two different experimental groups. No procedure was made in the control group except for the practice of the clinic. The results were analyzed using SPSS version 25. The mean ages of all groups were between 43.42 ± 8.60 and 47.22 ± 12.04 years. Fever, sore throat, dry mouth, cough, muscle weakness, and similar symptoms were present in all groups. Significant improvements were found in patients with hypoageusia and ageusia after date palm and salt application (p<0.01). For taste impairment caused by COVID-19, consumption of date palm and tasting very little salt for therapeutic purposes may help to alleviate taste impairment. Based on the data obtained from this study, the pathophysiology of the effects of date palm and salt on taste complications should be investigated.